CXCL12 and neoplasm: Under NOX-A12, all but one patient (90%) showed at best response reduced perfusion values in terms of relative cerebral blood volume (rCBV) (Supplementary Fig. 2) and threshold-calculated high fractional tumor burden (FTBhigh) with a median best response of −19.7% (24.0 to −55.5%) and −38.0% (9.3 to −100%) (Fig. 2e) indicating efficacy of the CXCL12 inhibitor therapy.